Arcus Biosciences, Inc.
Arcus Biosciences, Inc. (RCUS) Stock Ownership
Institutional vs insider vs public ownership from 13F and float data — top holders, activity, and insider trades below.
SEC 13F · FMP · RCUS · as of Sep 30, 2025
Ownership Breakdown
198
Institutional Holders
▲ 4 vs Q2
$1.37B
Total Inst. Value
▲ $556.39M vs Q2
100.67M
Shares Outstanding
freeFloat 75.44%
100.61M
13F Shares Held
▲ 857,706 vs Q2
Institutional ownership = 13F shares ÷ total outstanding. Insider % = 100 − free float. Public % = free float − institution %. Data: FMP /symbol-positions-summary + /shares-float + SEC EDGAR.
Top Institutional Holders
RCUS largest shareholders · institutional ownership
Q3 2025 · SEC 13F
Showing top 10 holders
| Holder | Shares | % Owned | Weight | Value | Reported | Change |
|---|---|---|---|---|---|---|
GILEAD SCIENCES, INC. pharmaceutical preparations | 31.42M | 29.62% | 29.62% | $427.38B | Nov 13, 2025 | — held |
BLACKROCK, INC. pharmaceutical preparations | 11.81M | 11.13% | 11.13% | $160.63B | Nov 12, 2025 | ▲ 352.9K |
VANGUARD GROUP INC pharmaceutical preparations | 6.63M | 6.25% | 6.25% | $90.16B | Nov 7, 2025 | ▲ 73.2K |
POINT72 ASSET MANAGEMENT, L.P. pharmaceutical preparations | 4.33M | 4.08% | 4.08% | $58.92B | Nov 14, 2025 | ▼ 1.63M |
WOODLINE PARTNERS LP pharmaceutical preparations | 3.77M | 3.55% | 3.55% | $51.27B | Nov 14, 2025 | ▼ 230.3K |
SUVRETTA CAPITAL MANAGEMENT, LLC pharmaceutical preparations | 3.69M | 3.48% | 3.48% | $50.17B | Nov 14, 2025 | — held |
STATE STREET CORP pharmaceutical preparations | 3.39M | 3.20% | 3.20% | $46.17B | Nov 14, 2025 | ▼ 236.0K |
SIREN, L.L.C. pharmaceutical preparations | 2.91M | 2.74% | 2.74% | $39.60B | Nov 13, 2025 | ▲ 1.30M |
FMR LLC pharmaceutical preparations | 2.30M | 2.16% | 2.16% | $31.23B | Nov 13, 2025 | ▼ 277.3K |
BALYASNY ASSET MANAGEMENT L.P. pharmaceutical preparations | 1.77M | 1.67% | 1.67% | $24.11B | Nov 14, 2025 | ▲ 65.0K |
Data from SEC Form 13F filings. Ownership bar normalised to largest holder. Change flags: isNew / isSoldOut / changeInSharesNumber (FMP extract-analytics/holder).
Institutional Activity
Q3 2025 vs prior quarter
Q3 2025
23
Increased
+5.20M shares5
New Positions
first time holders16
Decreased
−3.56M shares0
Sold Out
fully exitedNet shares change (top 50)
+1.63M
+5.20M / −3.56M
Net new holders
+12
5 new / 0 exited
Based on top 50 institutional holders by position size. Fields: isNew, isSoldOut, changeInSharesNumber (FMP extract-analytics/holder, limit=50).
Insider Buying vs Selling
RCUS insider trading · insider activity
Source: SEC Form 4
Insiders have been primarily selling shares recently. Selling may be driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment.
0
Buy transactions
2
Sell transactions
0.00
Buy/Sell ratio
$0M
Total disposed
Recent Insider Transactions
Showing 10 most recent · Common Stock only
| Name · Role | Date | Type | Shares | Price | Value | After Trans. | Filing |
|---|---|---|---|---|---|---|---|
Azoy Alexander Chief Accounting Officer | Jun 1, 2026 | Sale | 2,562 | $25.77 | $66.0K | 39.6K | Form 4 ↗ |
Ribas Antoni director | Dec 16, 2025 | Gift | 5,050 | — | — | 38.6K | Form 4 ↗ |
Goeltz II Robert C. Chief Financial Officer | May 11, 2026 | Sale | 7,763 | $25.63 | $199.0K | 84.2K | Form 4 ↗ |
Markus Richard Chief Medical Officer | Jan 23, 2026 | Award | 96,000 | $22.13 | $2.12M | 96.0K | Form 4 ↗ |
Markus Richard Chief Medical Officer | Jan 23, 2026 | Award | 24,000 | — | — | 89.6K | Form 4 ↗ |
ROSEN TERRY J Chief Executive Officer | Jan 23, 2026 | Award | 79,000 | — | — | 2.24M | Form 4 ↗ |
ROSEN TERRY J Chief Executive Officer | Jan 23, 2026 | Award | 315,000 | $22.13 | $6.97M | 315.0K | Form 4 ↗ |
Jaen Juan C. President | Jan 23, 2026 | Award | 31,000 | — | — | 377.0K | Form 4 ↗ |
Jaen Juan C. President | Jan 23, 2026 | Award | 126,000 | $22.13 | $2.79M | 126.0K | Form 4 ↗ |
Tang Carolyn C. General Counsel | Jan 23, 2026 | Award | 24,000 | — | — | 148.7K | Form 4 ↗ |
Source: /insider-trading/search (FMP stable). Buy/Sell direction: acquisitionOrDisposition A=Buy, D=Sell. RSU vesting (M-Exempt) excluded from sentiment bar. All data from SEC EDGAR public filings.
About institutional & insider ownership
Arcus Biosciences, Inc. (RCUS) is primarily owned by institutional investors, who hold approximately 99.9% of total shares outstanding. Company insiders own approximately 24.56%, while retail and public investors account for the remaining 0.00%.
The largest institutional shareholder of Arcus Biosciences, Inc. is GILEAD SCIENCES, INC., holding approximately 31.42 million shares — equal to 29.62% of outstanding shares — as of September 30, 2025.
A total of 198 institutional investors currently hold RCUS stock, with a combined institutional value of approximately $1.37 billion as of the most recent 13F filing period.
Frequently asked questions
RCUS ownershipArcus Biosciences, Inc. (RCUS) is primarily owned by institutional investors, who hold approximately 99.9% of shares. The largest shareholder is GILEAD SCIENCES, INC. with a 29.62% stake. Company insiders hold 24.56%. Data sourced from SEC Form 13F as of September 30, 2025.